RadNet (Nasdaq:RDNT) announced today that it acquired Gleamer SAS in a deal worth up to approximately $269.3 million (€230 million).
Gleamer, a Paris, France–based radiology AI company, will be integrated into DeepHealth, RadNet’s wholly owned subsidiary for clinical AI solutions for radiology. It adds to DeepHealth’s AI-powered health informatics solutions and services.
RadNet agreed to pay up to nearly $270 million in an all-cash transaction, which includes a post-closing milestone. It marks the second major AI acquisition for the company recently, which bought iCAD last year.
Gleamer, a fast-growing, cloud-first radiology AI company serves more than 700 customer contracts in 44 countries across Europe and beyond. It brings a multimodality portfolio of FDA-cleared and CE-marked clinical AI and workflow solutions. Those solutions span musculoskeletal, breast, lung and neurologic indications.
More about Gleamer and its integration into RadNet’s portfolio
RadNet plans to integrate Gleamer’s portfolio with DeepHealth’s clinical AI suites of solutions across breast, neuro, prostate and thyroid. The company said this creates a comprehensive portfolio “unrivalled by any other radiology AI company.
The combined portfolio supports screening, detection, interpretation and follow-up across several cancer types. It also extends to neurodegenerative and musculoskeletal conditions, such as trauma and chronic conditions.
Gleamer offers capabilities in automated reporting, RadNet said. Combining this with DeepHealth’s AI and informatics offerings can bring clinical, generative and agentic AI and imaging informatics together.
Additionally, the company says that deploying Gleamer’s radiology AI and workflow capabilities across its imaging network should create measurable productivity gains, especially in X-ray. RadNet plans to implement an end-to-end AI-enabled workflow as a result. This workflow begins with triaging critical findings to accelerate the interpretation of the most urgent cases.
The company said its acquisition could also accelerate the introduction of draft reporting capabilities. This would allow radiologists to increase reading volumes with greater accuracy and standardization. The approach enables RadNet to optimize internal resource utilization, improving operational and cost efficiencies.
Commentary from company officials
Dr. Howard Berger, president and CEO of RadNet, said:
“As imaging volumes continue to rise amid an accelerating shortage of radiologists worldwide, reengineering high-volume workflows — particularly routine imaging such as X-ray, ultrasound and mammography — is becoming essential to sustaining access, efficiency and quality of care. For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting. The acquisition of Gleamer uniquely positions DeepHealth to expand its impact across routine imaging and high-impact acute diagnostic care and accelerate the delivery of automated diagnostics.”
Christian Allouche, co-founder and CEO of Gleamer, said:
“Joining DeepHealth marks an exciting new chapter for our business and team members. Our team has been driven by a mission to improve patient care and access, and we are proud of the impact we have had on our customers and patients worldwide. By combining our AI capabilities, product portfolio and strong commercial team with that of DeepHealth, we are poised to shape the future of intelligent imaging at scale.”
Kees Wesdorp, president and CEO of DeepHealth, RadNet’s Digital Health Division, said:
“We welcome Gleamer’s team and capabilities into DeepHealth. This acquisition brings together two leaders on strong growth trajectories to create a new standard of AI-powered care. By building on our combined strengths, we are redefining how imaging is delivered, at scale, with intelligence and automation, to advance access and efficiency while improving experiences and outcomes for patients and providers worldwide.”
